



INSIDE THIS ISSUE

- Protocol Update – UCNTEMOZ
- Cancer Management Manual
- Drug Update – Chlorambucil, Thalidomide
- Pre-Printed Order Update - LYCHOP
- Provincial Systemic Therapy Program Policies – Cytotoxic Drug Handling (V-10), Spill Management of Cytotoxic Agents (V-30)

FAX request form and IN TOUCH phone list are provided if additional information is needed.

PROTOCOL UPDATE

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- UCNTEMOZ reformatted (dose modifications clarified): Second line therapy for recurrent malignant gliomas using temozolomide

CANCER MANAGEMENT MANUAL

The Cancer Management Manual is available on BCCA website <http://www.bccancer.bc.ca/cmm/>.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- LYCHOP new: Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP).
- An index to the orders can be obtained by Fax-back.

DRUG UPDATE

Thalidomide Approval and Drug Ordering

Obtaining Health Canada Special Access Program (SAP) approval and purchasing thalidomide remain the responsibility of the hospital (i.e., physician, pharmacist) from which the patient will be dispensed the drug. BCCA regional cancer centres will **NOT** be responsible for these tasks unless the thalidomide is to be dispensed directly to the patient from that regional cancer centre.

Some physicians outside the regional cancer centres have inadvertently been provided with a “Request for Thalidomide from Celgene and SAP Program of Health Canada” form. This form instructs them to complete the form and FAX it to their BCCA Pharmacy, who would then forward it to SAP and to the manufacturer. **Please note that this form was developed for use within the regional cancer centres only.** It was never intended for submission to the regional cancer centres’ pharmacies to order thalidomide for patients being treated from outside the regional cancer centres.

Physicians who wish to prescribe thalidomide for a patient being treated outside the regional cancer centres must first obtain BCCA Undesignated Approval in the usual manner, then contact the SAP directly for authorisation. The SAP will then arrange the provision of thalidomide to the local hospital pharmacy, which will be responsible for the cost and subsequent claim to BCCA for reimbursement.

Chlorambucil Shortage

Chlorambucil tablets may be temporarily unavailable from the manufacturer. In the interim, the BCCA Lymphoma Tumour Group recommends that oral cyclophosphamide be substituted for oral chlorambucil to manage patients with low-grade lymphoma or chronic lymphocytic leukaemia as follows:

**PROVINCIAL SYSTEMIC THERAPY
PROGRAM POLICIES**

- For chlorambucil 0.4 mg/kg po once every 2 weeks, substitute cyclophosphamide 300 mg/m² po once every 2 weeks.
- For other chlorambucil doses on a once every 2 week schedule, adjust the cyclophosphamide dose proportionately. The maximum dose is cyclophosphamide 600 mg/m² po once every 2 weeks.

Chlorambucil mg/kg po q2w	Cyclophosphamide mg/m² po q2w
0.4	300
0.5	375
0.6	450
0.7	525
0.8	600

- For chlorambucil 0.2 mg/kg/day po x 21 days q6w or chlorambucil 0.1 mg/kg/day po continuously, there is no safe substitute dose of oral cyclophosphamide. Physicians should consider using the once every 2 week schedule until chlorambucil tablets are again available. The usual starting dose is cyclophosphamide 300 mg/m² po once every 2 weeks. Increase by 75 mg/m² every other treatment until mild leukopenia (ANC < 3.5 x 10⁹/L) or definite tumour response is documented. Do not exceed 600 mg/m² po once every 2 weeks. Patients should stop the continuous chlorambucil at least 3 weeks prior to starting this new schedule of oral cyclophosphamide.
- Monitoring and dose modifications remain the same as for chlorambucil (refer to BCCA protocol LYCHLOR).

Please contact BCHS or GlaxoWellcome for information on the expected date of availability. If needed, please contact your regional Lymphoma Tumour Group representative for additional information regarding substituting oral cyclophosphamide for chlorambucil.

Cytotoxic Drug Handling

The BCCA Provincial Systemic Therapy Program Risk Management Policy V-10 (Safe Handling Standards of Cytotoxic Agents) has been revised and approved at July PSTP meeting. The revision incorporated the new Workers Compensation Board Regulations on maintaining cytotoxic exposure records for the duration of employment of each employee plus 10 years, and training records of 3 years from the date training occurred.

Spill Management

The BCCA Provincial Systemic Therapy Program Risk Management Policy V-30 (Spill Management of Cytotoxic Agents) has been revised to add clean-up procedure guidelines for linens and clothing.

Editorial Review Board

Mário de Lemos, PharmD (Editor)
Robin O'Brien, PharmD (acting Editor)

Sharon Allan, MD
Sandi Broughton, BA(Econ), MSc
Jack Chritchley, MD
Linda Yearwood, MSN
Lynne Nakashima, PharmD
David Noble, BSc, BLS
Lynn Stevenson, RN
Kelly Uyeno, CGA

Gigi Concon (Secretary)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	bfiddler@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	francish@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Policies	H:\everyone\systemic\chemo\Policies
	V_10: Cytotoxic Agents, Safe Handling Standards
	V_30: Spill Management of Cytotoxic Agents
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
	LYCHOP
Index of Pre-Printed Orders	Index or Index_W6
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\tumour site"
	UCNTEMOZ
Index of Protocol Summaries	Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List	BenefitList
Class 2 Form	Class2

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca

BCCA SYSTEMIC THERAPY UPDATE**FAX REQUEST FORM**

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247****PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES***I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:* E-mail (Word 6.0)

@

 Fax

()

Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/>	All items
Policies	
<input type="checkbox"/>	V_10: Cytotoxic Agents, Safe Handling Standards
<input type="checkbox"/>	V_30: Spill Management of Cytotoxic Agents
Pre-Printed Orders:	
<input type="checkbox"/>	LYCHOP
<input type="checkbox"/>	Index: Pre-Printed Orders
Protocol Summaries:	
<input type="checkbox"/>	UCNTEMOZ
<input type="checkbox"/>	Index: Protocol Summaries (current month)
Reimbursement	
<input type="checkbox"/>	Benefit Drug List (1 August 2000)
<input type="checkbox"/>	Class 2 Form (1 August 2000)
Systemic Therapy Update Index	
<input type="checkbox"/>	Jan-Jun 2000